Business
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease
About this update from Novartis Ag
[{"type":"text","content":"ROCKVILLE, Md. , Jan. 12, 2026 /PRNewswire/ --","length":51,"tagName":"p"},{"type":"image","alt":"SciNeuro Pharmaceuticals Logo (PRNewsfoto/SciNeuro Pharmaceuticals)","displaySize":"","headline":null,"caption":"SciNeuro Pharmaceuticals Logo (PRNewsfoto/SciNeuro Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/prnewswire.com/61f2b1d7aa805e59d9c5d4738d111f85"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wk8lX3ft5mPiAGD4s10HLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/61f2b1d7aa805e59d9c5d4738d111f85","width":400,"height":283}},"href":"https://mma.prnewswire.com/media/1827703/SciNeuro_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"list","items":[{"val":[{"type":"text","content":"SciNeuro grants Novartis an exclusive worldwide license to develop SciNeuro's novel antibody program that leverages a proprietary shuttle technology to enhance brain delivery of therapeutic agents to treat Alzheimer's Disease","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"SciNeuro and Novartis will collaborate during early development, with Novartis leading subsequent development and commercialization worldwide","length":141,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":374,"olType":false},{"type":"text","content":"SciNeuro Pharmaceuticals today announced it has entered into a worldwide licensing and collaboration agreement with Novartis Pharma AG, to advance SciNeuro's novel amyloid beta targeted antibody program for the treatment of Alzheimer's Disease. The program has identified de novo antibody candidates that incorporate SciNeuro's proprietary blood brain barrier shuttle technology and offer potential differentiation from existing amyloid beta targeted agents.","length":470,"tagName":"p"},{"type":"text","content":"SciNeuro and Novartis will collaborate during early development. Novartis will lead all subsequent product development and commercialization on a worldwide basis.","length":162,"tagName":"p"},{"type":"text","content":""The anti-amyloid program represents one of SciNeuro's key strategic R&D priorities to target neurodegenerative disease. We are thrilled to collaborate with Novartis to continue its development, give...